Europe and Japan Allergy Immunotherapy Market Soars by 2032: Personalized Treatment and Rising Allergy Cases Drive Regional Demand

The Europe and Japan Allergy Immunotherapy Market represents a critical segment within the broader pharmaceutical and healthcare industry, characterized by an increasing prevalence of allergic rhinitis, asthma, and other hypersensitivity disorders. Rising demand for targeted allergy management solutions combined with technological advances in immunotherapy techniques underpins significant business growth. The market size for the Europe and Japan Allergy Immunotherapy Market is estimated to be valued at USD 2.8 billion in 2025 and is expected to reach USD 4.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032. This steady market growth is driven by intensified research initiatives, policy focus on allergy treatment protocols, and expanding patient awareness.

Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/5037

➤Actionable Insights

● Production capacity for allergy immunotherapy products has seen a 12% increase across major pharmaceutical facilities in Europe and Japan during 2024, indicating supply-side expansion.
● Pricing trends reveal that sublingual immunotherapy formulations have gained cost competitiveness, registering an average price reduction of 5% in 2024.
● Import volumes of standardized allergen extracts surged by 9% in 2024, reflecting diversified sourcing to meet rising demand.
● Various applications span respiratory allergies, insect venom therapies, and food allergy management, with respiratory allergy immunotherapy accounting for over 60% of total market revenue in 2024.
● Micro-segmentation analysis shows a significant rise in pediatric allergy immunotherapy sessions in Japan, increasing by 15% year-over-year, driven by early intervention initiatives.

➤Market Segment and Regional Coverage

● By Therapy Type: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), Oral Immunotherapy (OIT), and Others.
● By Indication: Respiratory Allergies, Food Allergies, Insect Venom Allergies, and Others.
● By End-User: Hospitals, Specialty Clinics, Home Care Settings, and Others.

Regional and Country Analysis:

● North America: U.S. and Canada (not covered in this report)
● Latin America: Brazil, Argentina, Mexico, and Rest of Latin America (not covered)
● Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
● Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
● Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA (not covered)

The Europe segment remains a mature market with consistent innovation in sublingual vaccines, while Japan continues to witness rapid growth attributable to government-backed immunotherapy programs and enhanced diagnostic infrastructure.

➤Key Players

● ALK-Abelló A/S
● Stallergenes Greer
● DBV Technologies
● Torii Pharmaceutical Co., Ltd.
● Sanofi S.A.
● Bencard Allergie GmbH
● LETI Pharma
● Allergy Therapeutics Plc
● Meda Pharma (part of Mylan)
● Forsyth Pharmaceuticals
● Jubilant Life Sciences
● Greer Laboratories
● Biomay AG
● Laboratorios LETI
● BIOCAD

● Strategic collaborations stand out, such as ALK-Abelló's partnership with a Japanese pharmaceutical company in 2024, resulting in accelerated market penetration and a 10% increase in sales volume in Japan by Q3 2025.
● Stallergenes Greer adopted a focused R&D strategy emphasizing personalized immunotherapy solutions, which enhanced its competitive positioning across European markets, increasing market share by approximately 5% in 2024.

Get Full Report: https://www.coherentmarketinsights.com/market-insight/europe-and-japan-allergy-immunotherapy-market-5037?utm_source=openpr.com&utm_medium=referral

➤Growth factors

● Increasing allergy prevalence in both Europe and Japan, with the European Respiratory Society reporting a 14% rise in allergic rhinitis cases between 2023 and 2024.
● Advances in peptide and recombinant DNA technology boosting immunotherapy efficacy and patient compliance.
● Government incentives supporting immunotherapy research initiatives contributed approximately USD 150 million in funding earmarked for 2024-2025 in Japan.
● Rising demand for minimally invasive sublingual therapies, evidenced by a 20% year-over-year patient adoption increase in Europe during 2024.

➤ Market Trends

● The growing trend of personalized allergy immunotherapy, accentuated by biomarker-driven patient stratification, has led to tailored treatment regimens improving clinical outcomes since early 2025.
● Enhanced digital health tools and telemedicine adoption emerged as vital components for patient monitoring post-immunotherapy, especially significant in Japan's widespread rural populations.
● An uptick in oral immunotherapy clinical trials for food-related allergies was recorded globally in 2024, with Europe and Japan showing particular research activity contributing to evolving treatment protocols.
● Sustainability in manufacturing allergen extracts gained traction in 2025, with leading players integrating green chemistry principles to minimize environmental footprint.

➤Key Takeaways

● Respiratory allergies represent the dominant indication segment, driven by high incidence in urban Europe and Japan.
● Sublingual immunotherapy is a leading therapy type, favored for non-invasive administration and improved patient adherence.
● Hospitals remain the primary end-users, accounting for the majority of immunotherapy delivery due to advanced clinical settings.
● Europe exhibits advanced market dynamics with established regulatory frameworks promoting innovation.
● Japan is a fast-growing regional market, buoyed by government support and technology adoption.
● Market challenges involve regulatory heterogeneity and need for standardized immunotherapy protocols across regions.

📌 Get Instant Access! Purchase Research Report and Receive a 25% Discount with limited-time offer! https://www.coherentmarketinsights.com/insight/buy-now/5037

❓ Frequently Asked Questions

1. Who are the dominant players in the Europe and Japan Allergy Immunotherapy Market?
The dominant market players include ALK-Abelló A/S, Stallergenes Greer, DBV Technologies, Torii Pharmaceutical Co., Ltd., and Sanofi S.A., which lead through innovation and strategic partnerships.

2. What will be the size of the Europe and Japan Allergy Immunotherapy Market in the coming years?
The market size is projected to grow from USD 2.8 billion in 2025 to USD 4.7 billion by 2032, at a CAGR of 7.2%, reflecting strong market growth and opportunities.

3. Which end users industry has the largest growth opportunity?
Hospitals represent the largest end-user segment, with advanced immunotherapy capabilities and high volumes of allergy patients seeking professional treatment.

4. How will market development trends evolve over the next five years?
Market trends will focus on personalized treatment approaches, greater adoption of sublingual immunotherapy, integration of digital health, and increased sustainability efforts in production.

5. What is the nature of the competitive landscape and challenges in the Europe and Japan Allergy Immunotherapy Market?
Competition is driven by innovation, partnerships, and geographic expansion, with challenges including regulatory complexities and market adaptation to evolving clinical guidelines.

6. What go-to-market strategies are commonly adopted in the Europe and Japan Allergy Immunotherapy Market?
Key strategies include targeted R&D investments, collaborations with local pharmaceutical entities, patient awareness programs, and launch of novel immunotherapy formulations catering to regional needs.

✍️ PR Authored By:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report.

About Us:

With a proven excellence in market research, Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

☎️ Contact Us:

533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
United States of America: + 12524771362
United Kingdom: UK Number: +442039578553
Australia: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com

This release was published on openPR.